Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis

Zhang, Lin L; Guo, Jing; Duan, Kai

doi:10.5114/ceji.2019.92808

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the reported data, 92.6% of them were men and the other (7.4%) were women. The most common mode of transmission in Iran is shared use of needles (69.8%), unknown cases (19.5%), sexual contact (8.9%), infected blood (1.2%) and finally mother-to-child (0.6%) [8,9].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of hepatitis B in HIV-positive patients in Zabol

Rezaie-Kahkhaie

Saravani

Keikhaie

et al. 2021

Cell. Mol. Biomed. Rep.

View full text Add to dashboard Cite

Today, due to the increase in life expectancy in HIV-infected patients, the incidence of related diseases such as hepatitis B and C due to similarity in transmission routes has become a major concern of the health community. Therefore, this study was performed to determine the prevalence of hepatitis B among HIV + patients in Zabol. This descriptive cross-sectional study was performed on 37 HIV-infected patients in Zabol city (2021)(2022). In the present study, HIV-infected patients were screened for hepatitis B by measuring serum levels of HBC Ab and HBs Ag. Finally, the data in SPSS V21 software were analyzed. In the present study, a total of 37 HIV-infected patients with a mean age of 40.81-11.64 years were evaluated. The present study's prevalence of HIV and HCV coinfection was 21.6%. Also, 13.5% of HIV patients had HBV and HCV simultaneously. Examination of risk factors for viral hepatitis in HIVinfected patients showed that unprotected sex (100%), injecting drug use or IDU (87.5%), dental procedures (75%), history of imprisonment (62.5%) and tattooing (50.5%) were the most common factors in HIV patients. Family history of hepatitis B (12.5%), alcohol (12.5%), transfusion (12.5%) and cupping (25%) were among the lowest cases in these patients. the frequency of HBV infection and co-infection with HCV and HBV in HIV-positive patients were relatively high. Except for the history of tattoos, there is no significant relationship between other risk factors and hepatitis B among HIV-positive patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence of hepatitis B in HIV-positive patients in Zabol

Rezaie-Kahkhaie

Saravani

Keikhaie

et al. 2021

Cell. Mol. Biomed. Rep.

View full text Add to dashboard Cite

show abstract

Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses

Qiu,

Zhang,

Feng

et al. 2023

Expert Review of Vaccines

View full text Add to dashboard Cite

Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer’s disease pathology in aged squirrel monkeys

Patel

Nehete

Krivoshik

et al. 2021

Brain

View full text Add to dashboard Cite

Alzheimer’s disease is the most common cause of dementia and the only illness among the top 10 causes of death for which there is no disease-modifying therapy. The failure rate of clinical trials is very high, in part due to the premature translation of successful results in transgenic mouse models to patients. Extensive evidence suggests that dysregulation of innate immunity and microglia/macrophages plays a key role in Alzheimer’s disease pathogenesis. Activated resident microglia and peripheral macrophages can display protective or detrimental phenotypes depending on the stimulus and environment. Toll-like receptors (TLRs) are a family of innate immune regulators known to play an important role in governing the phenotypic status of microglia. We have shown in multiple transgenic Alzheimer’s disease mouse models that harnessing innate immunity via TLR9 agonist CpG oligodeoxynucleotides (ODNs) modulates age-related defects associated with immune cells and safely reduces amyloid plaques, oligomeric amyloid-β, tau pathology, and cerebral amyloid angiopathy (CAA) while promoting cognitive benefits. In the current study we have used a non-human primate model of sporadic Alzheimer’s disease pathology that develops extensive CAA—elderly squirrel monkeys. The major complications in current immunotherapeutic trials for Alzheimer’s disease are amyloid-related imaging abnormalities, which are linked to the presence and extent of CAA; hence, the prominence of CAA in elderly squirrel monkeys makes them a valuable model for studying the safety of the CpG ODN-based concept of immunomodulation. We demonstrate that long-term use of Class B CpG ODN 2006 induces a favourable degree of innate immunity stimulation without producing excessive or sustained inflammation, resulting in efficient amelioration of both CAA and tau Alzheimer’s disease-related pathologies in association with behavioural improvements and in the absence of microhaemorrhages in aged elderly squirrel monkeys. CpG ODN 2006 has been well established in numerous human trials for a variety of diseases. The present evidence together with our earlier, extensive preclinical research, validates the beneficial therapeutic outcomes and safety of this innovative immunomodulatory approach, increasing the likelihood of CpG ODN therapeutic efficacy in future clinical trials.

show abstract

Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis

Cited by 3 publications

References 30 publications

Prevalence of hepatitis B in HIV-positive patients in Zabol

Prevalence of hepatitis B in HIV-positive patients in Zabol

Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses

Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer’s disease pathology in aged squirrel monkeys

Contact Info

Product

Resources

About